🇺🇸 AXITINIB in United States

1,645 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 287 reports (17.45%)
  2. Hypertension — 197 reports (11.98%)
  3. Fatigue — 191 reports (11.61%)
  4. Death — 183 reports (11.12%)
  5. Malignant Neoplasm Progression — 165 reports (10.03%)
  6. Off Label Use — 163 reports (9.91%)
  7. Disease Progression — 120 reports (7.29%)
  8. Neoplasm Progression — 118 reports (7.17%)
  9. Decreased Appetite — 112 reports (6.81%)
  10. Hypothyroidism — 109 reports (6.63%)

Source database →

AXITINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is AXITINIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for AXITINIB in United States?

Marketing authorisation holder not available in our data.